Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (Nasdaq: LFWD) will effect a 1-for-12 reverse share split effective at market open on February 24, 2026, combining every twelve issued ordinary shares into one share and assigning a new CUSIP (M8216Q309).
The Board also increased authorized share capital to 100,000,000 shares. The company expects shares outstanding to fall from ~18.3 million pre-split to ~1.5 million post-split and says the move aims to meet Nasdaq's $1.00 bid-price continued listing standard.
Lifeward (Nasdaq: LFWD) announced on Feb 17, 2026 that Aetna issued a prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, joining Humana and UnitedHealthcare.
Coverage now spans three major Medicare Advantage insurers, representing approximately 16 million beneficiaries, for qualified individuals meeting medical necessity criteria.
The ReWalk Personal Exoskeleton is FDA-approved; peer-reviewed studies cited benefits for ambulation, musculoskeletal health, and cardiopulmonary function.
Lifeward (Nasdaq: LFWD) entered a strategic partnership with Oramed (Nasdaq: ORMP) under which Lifeward will acquire Oramed's clinical-stage POD™ protein oral delivery platform and Oramed may acquire up to 49.99% of Lifeward. The transaction provides Lifeward access to up to $47 million via equity, convertible notes, milestone funding and warrants, and includes Oramed funding and managing planned POD™ clinical work.
The deal includes a 4% net-sales royalty on ReWalk for up to 10 years and preserves Lifeward’s focus on achieving cash‑flow profitability while adding biotech upside tied to oral insulin and other protein therapies.
Oramed Pharmaceuticals and Lifeward (NASDAQ: LFWD) signed binding agreements dated January 13, 2026 to transfer Oramed's POD™ oral drug delivery platform to Lifeward in exchange for Oramed receiving a 49.9% beneficial ownership interest upon satisfaction of closing conditions. Lifeward will issue two $10 million senior secured convertible notes (8% interest) with 100% warrant coverage; Oramed to invest $9M in each note. Oramed will fund and manage the upcoming clinical trial and receive 4% of net ReWalk sales for up to 10 years. Lifeward reported $26M revenue from ReWalk and AlterG in the last four quarters.
Lifeward (Nasdaq: LFWD) announced that its Board appointed Bob Marshall as Chairman, effective January 1, 2026. He will replace Joseph Turk, who will transition off the Board in connection with his new role at Fresenius Medical Care as Chief Executive Officer of Care Enablement.
Marshall has served on Lifeward's Board and as Chair of the Audit Committee since 2024, and is currently CFO and Treasurer of Lantheus Holdings (roles held since 2018). Management says Marshall’s financial leadership and public-company healthcare experience will support Lifeward’s strategic growth plans and patient-care objectives.
Lifeward (Nasdaq: LFWD) announced a distribution agreement with Singapore-based Verita Neuro to exclusively distribute the ReWalk Personal Exoskeleton initially in Mexico, Thailand, and the United Arab Emirates effective Dec. 17, 2025.
Verita will integrate ReWalk into intensive, daily in-patient neurorehabilitation programs and offer patient-specific setup and training, leveraging an international database of >25,000 spinal cord injury patients. Lifeward said the partnership supports a partner-led, capital-efficient commercial expansion and cites a $1.75 billion total addressable market for ReWalk.
Lifeward (Nasdaq: LFWD) announced that a Humana Medicare Advantage plan granted prior authorization for the ReWalk 7 personal exoskeleton on Dec 3, 2025, following a prior UnitedHealthcare approval in November.
Combined, Humana and UnitedHealthcare represent 47% of Medicare Advantage enrollees, increasing timely access for beneficiaries with spinal cord injury. The company said broader payer adoption and CMS's 2024 reimbursement pathway are improving reimbursement predictability and supporting stronger revenue and cash flow dynamics for U.S. scaling.
Lifeward (Nasdaq: LFWD) announced on Nov 17, 2025 that a UnitedHealthcare Medicare Advantage plan issued a prior authorization for a ReWalk 7 Personal Exoskeleton. The approval follows CMS's 2024 reimbursement pathway for personal exoskeletons and is presented as a step toward broader payer adoption in the U.S.
The company said the UnitedHealthcare prior authorization may improve predictability in reimbursement, accelerate prior authorizations, and support scalable growth and cash flow dynamics for beneficiaries using ReWalk 7.
Lifeward (Nasdaq: LFWD) reported Q3 2025 results on Nov 14, 2025: revenue $6.2M (Q3 2024: $6.1M), net loss $3.2M or $0.20 per share, and cash used in operations $3.8M.
Key operational progress included a record quarter of ReWalk placements for Medicare beneficiaries, a 16% year‑over‑year reduction in quarterly cash burn, a 27% decline in quarterly non‑GAAP operating loss, and CE mark approval for ReWalk 7 enabling sales in Europe (~40% of exoskeleton sales). Lifeward also secured a $3.0M loan from Oramed and reaffirmed 2025 guidance of $24–$26M revenue and $12–$14M non‑GAAP net loss.
Lifeward (NASDAQ: LFWD) will release its third quarter 2025 financial results before markets open on Friday, November 14, 2025. A conference call and live webcast with CEO Mark Grant and CFO Almog Adar is scheduled for 8:30 a.m. EST the same day to discuss results.
Analysts and investors can join via toll-free U.S. dial-in 1-833-316-0561, international dial-in 1-412-317-0690, or regional numbers including Germany and Israel; participants should reference the "Lifeward Earnings Call" access code. The live webcast is available on the company website GoLifeward.com in Investors or at https://edge.media-server.com/mmc/p/522gfyx4, with an archived replay to follow on the site.